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Abstract
Background: Vascular dysfunction and brain inflammation are thought to contribute to the pathophysiology of
cerebral injury in acute stroke. However acute inflammation and vascular dysfunction may simply be markers of an
acute phase response to cerebral injury, reflecting the size of the cerebral lesion. We aimed to determine if
systemic markers of vascular dysfunction and inflammation are independently associated with concentrations of
the astroglial protein S100B, a marker of brain injury, in participants with acute ischaemic stroke.
Methods: Fifty-seven men and women recruited within 96 hours of acute ischaemic stroke at two tertiary hospitals
participated in this cross sectional observational study. Clinical, imaging (stroke lesions area measured with
perfusion CT) and laboratory data were the independent variables and co-variates. The outcome variable was
serum S100B concentration, analysed by multivariate regression.
Results: High sensitivity-CRP (B = 0.41) and lesion area (B = 0.69) were independently associated with S100B
concentration (R
2 = 0.75, p < 0.01). Other variables with significant univariate associations with S100B concentration
were not independently associated with S100B concentration in the final multivariate model.
Conclusion: The degree of systemic inflammation is associated with S100B concentration in acute ischaemic
stroke, independent of the size of the ischaemic lesion.
Background
Acute ischaemic stroke is associated with a rise in
systemic markers of endothelial activation, inflammation
and oxidative stress [1-6]. At the site of brain injury vas-
cular dysfunction, oxidative stress and brain inflamma-
tion are thought to contribute to the pathophysiology of
cerebral injury in acute stroke [2,7]. However, it is
uncertain whether these factors simply represent an
“acute phase” response to the cerebral injury, and asso-
ciated complications such as immobility, or are impor-
tant independent predictors of the degree of cerebral
injury resulting from an acute ischaemic insult.
Much evidence shows that inflammation in the setting
of acute ischaemic stroke is associated with infarct size,
supporting the hypothesis th a ti n f l a m m a t i o ni na c u t e
stroke primarily reflects an acute phase response deter-
mined by the degree of cerebral injury [1,8]. However
the magnitude of the acute phase response appears to
also be independent an predictor of clinical outcome
[9]. In patients with lacunar syndromes, who tend to
have small volume lesions, progression of neurologic
symptoms is associated with markers of the acute phase
response [10]. These data suggest that inflammation
may be an important independent factor in the patho-
physiology of acute ischaemic stroke.
S100B is a peptide derived largely from astrocytes. In
normal physiology S100B has multiple local regulatory
effects on cell division and metabolism. Ischaemia is
associated with raised S100B levels [11,12]. This is
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concentrations are marker of the degree and severity of
cellular injury in acute ischaemic stroke.
We conducted this study to test the hypothesis that
endothelial function, inflammation and oxidative stress
are independently associated with the degree of cellular
injury in acute ischaemic stroke. We aimed to determine
if endothelial function, inflammation and oxidative stress
are associated with S100B concentration in acute ischae-
mic stroke, and in particular if any association is inde-
pendent of infarct size.
Methods
Design
Cross-sectional observational study.
Setting and participants
Patients were recruited at two teaching hospitals in
Perth, Western Australia between May 2005 and Novem-
ber 2008. Patients admitted with acute ischaemic stroke
within 96 hours of onset were eligible to participate.
Exclusion criteria were: blood glucose level > 13 mmol/L;
acute co-morbid condition; creatinine >120 umol/L; hae-
morrhage seen on initial CT; and history of sensitivity to
contrast. Clinical records were reviewed subsequent to
the patient’s discharge to confirm a final clinical diagno-
sis of an acute cerebral ischaemic event and classify the
clinical syndrome using the Oxfordshire Community
Stroke Project classification [13].
Assessments
Clinical characteristics were assessed using the National
Institutes of Health Stroke Scale (NIHSS), [14] Modified
Barthel Index (MBI) [15] and Modified Rankin Scale
(MRS) [16]. Laboratory data were collected to assess
S100B concentrations [11], inflammation (C-reactive
protein [CRP] and fibrinogen [9]), endothelial activation
(E-selectin [1]), endothelial cell damage (Von Willebrand
factor [vWF] [1]) and oxidative stress [F2-isoprostanes]
[4]). With the exception of F2-isoprostanes, all assays
were performed by the PathWest Laboratory Medicine
Units at Royal Perth and Sir Charles Gairdner Hospitals,
using routine collection and analysis procedures. For
analysis of F2-isporostanes, 5 ml of whole venous blood
was collected into cold EDTA tubes containing reduced
glutathione and centrifuged as soon as possible at 1000
g for 10 min at 4°C. The plasma was protected from
oxidation by the addition of butylated hydroxytoluene at
a final concentration of 20 μg/ml plasma and stored at
-80°C until analysis by gas chromatography/mass spec-
trometry [17]. Blood pressure was assessed using vali-
dated
, [18,19] oscillometric ambulatory blood pressure
monitors (Oscar 2, SunTech Medical, Morrisville NC
USA) worn by participants for 24 hours after enrolment.
Participants underwent perfusion CT scanning. Five
patients were imaged prior to July 2005. A single
10 mm slice was taken at the level of the third ventricle.
C y c l et i m ew a s1s .S u b s e q u e n tt oJ u l y2 0 0 58s l i c e s
were acquired on mulitdetector machines (Philips Brilli-
ance 64 slice scanner). 40 mL of non-ionic contrast
(‘Optiray’) was administered over 10 seconds using an
intravenous cannula in the antecubital fossa. The multi-
detector machine protocol was: length 40 mm, thickness
5 mm, increment 0 mm, kV 120, mAs 100, cycle time
1.5, cycles 45, Resolution High, Collimation 32 × 1.25,
Rotation time 0.4 sec, Filter Smooth UA, matrix 512.
Post processing and analysis was completed on Philips
and GE workstations. When multiple slices were avail-
able, the slice with greatestl e s i o na r e ae v i d e n to nt h e
plain CT was chosen for analysis. Infarct size was mea-
sured by an experienced neuroradiologist (MB) blinded
to treatment allocation.
Data analysis
SPSS for MS Windows was used to analyse data. Log-
normal data were log transformed prior to analysis.
Non-normal data were analysed using non parametric
tests. Categorical variables were assessed with the chi
squares or fisher exact test. Linear regression modeling
was used to examine the association between predictor
variables and concentration of S100B. Only non-missing
data were included in the modeling exercise. This com-
menced with a series of univariate models to identify all
candidate predictor variables. These significant variables
were then included in a multivariate logistic regression
model and removed using a backward stepwise process
if their significance was not retained. Box-plots of the
remaining variables were re-inspected to ensure that
outlying values were not present, before producing the
final parsimonious model.
Ethical considerations
T h es t u d yw a sa p p r o v e db yt h eR o y a lP e r t ha n dS i r
Charles Gairdner Hospitals Ethics Committees. Able
participants provided written informed consent. If there
was uncertainty regarding the person’s ability to provide
informed consent agreement to study participation was
also sought from the person’s next of kin. The proce-
dures followed were in accordance with the Helsinki
Declaration.
Results
Cohort characteristics
An heterogeneous group of 57 acute ischaemic stroke
patients participated in the study (Table 1). The mean
age of participants was 68 years. Participants were
enrolled a mean of 53 hours after the onset of symp-
toms. Although there was wide variability in the sample,
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mean NIH stroke scale score was 10, 40% of participants
had a modified Rankin score of 4 or 5 and the mean
lesion area was 10 cm
2).
Factors associated with S100B concentrations
Significant univariate associations were found between
age, stroke syndrome, neurologic impairment (NIHSS
Score), disability (Modified Barthel Index score), lesion
area, hs-CRP and serum concentration of S100B. These
are shown in Table 2. However, of these factors, only
hs-CRP (B = 0.41) and lesion area (B =0 . 6 9 )r e m a i n e d
independently associated with S100B concentration in
the final parsimonious multivariate model. Results of this
model are also listed in Table 2. The multivariate model,
including 54 participants with no missing data, showed
that hs-CRP and lesion area explained the majority of
variance in S100B (Adjusted R
2 = 0.76, p < 0.01).
Discussion
Main findings
These data show that the relationship between S100B
concentration and inflammation in participants with
acute ischaemic stroke is independent of infarct size.
These data establish an independent association between
markers of inflammation and glial injury, suggesting that
the inflammatory response to acute ischaemic injury
may be a therapeutic target. The concept that limiting
inflammation may limit brain injury is supported by evi-
dence that components of the acute phase response to
cerebral injury are deleterious. For example, CRP is
Table 1 Cohort characteristics
Variable Mean ± SD or n(%)
Age (years) 67.8+13.7
Male (%) 39 (68%)
Enrolled (hours) 52.6 ± 21.6
Hypertension 35 (61%)
Atrial fibrillation 10 (18%)
Hypercholesterolaemia 11 (19%)
Diabetes 13 (23%)
Smoking 21 (37%)
Aetiology
Large vessel 6 (11%)
Small vessel 8 (14%)
Cardioembolic 24 (42%)
Other 1 (2%)
Unknown 18 (32%)
Syndrome
Total anterior circulation 14 (25%)
Partial anterior circulation 26 (46%)
Lacunar 11 (19%)
Posterior circulation 6 (11%)
Systolic blood pressure (mmHg) 142.1 ± 19.3
Diastolic blood pressure (mmHg) 80.2 ± 11.2
NIH stroke scale score 8.5 ± 7.8
Modified Rankin scale score
0-3 17 (30%)
4-5 40 (70%)
Modified Barthel index score 39.3 ± 33.9
Glucose (mmol/L) 6.3 ± 1.6
Homocysteine (umol/L) 9.9 ± 3.8
High sensitivity-CRP (mg/L) 15.7 ± 27.9
Fibrinogen (g/L) 4.2 ± 1.2
E-selectin (ng/mL) 30.5 ± 34.0
von Willebrand Factor (%) 158.7 ± 61.6
S100B (ug/L) 0.5 ± 0.8
F2-Isoprostanes (nmol/L) 3.2 ± 4.2
Lesion area (mm
2) 1001.9 ± 1359.8
Table 2 Univariate and multivariate relationships (S100B
as dependent variable) analysed by linear regression
Predictor B SE B B p
Univariate Relationships
Age 0.01 0.01 0.27 0.05
Gender -0.10 0.18 -0.07 0.60
Hours to enrolment 0.00 0.00 0.07 0.62
Hypertension -0.06 0.17 -0.05 0.73
Atrial fibrillation 0.19 0.22 0.12 0.40
Hypercholesterolaemia -0.20 0.22 -0.12 0.37
Diabetes 0.02 0.20 0.02 0.90
Smoking history -0.09 0.17 -0.07 0.60
Aetiology -0.03 0.06 -0.06 0.66
Clinical syndrome -0.43 0.08 -0.61 0.00
Systolic blood pressure 0.00 0.00 0.00 0.99
Diastolic blood pressure 0.00 0.01 -0.07 0.58
NIHSS score 0.56 0.20 0.36 0.01
Modified Rankin 0.00 0.00 1.10 0.28
Modified Barthel -0.01 0.00 -0.36 0.01
Glucose 1.52 0.84 0.25 0.08
Homocysteine 0.01 0.52 0.00 0.99
Hs-CRP 0.56 0.12 0.55 0.00
Fibrinogen 0.10 0.07 0.20 0.16
E-Selectin -0.09 0.29 -0.04 0.75
von Willebrand factor activity 0.00 0.00 2.26 0.03
F2-Isoprostanes 0.04 0.31 0.02 0.89
Lesion area 0.73 0.08 0.77 0.00
Final multivariate model
Hs-CRP 0.42 0.07 0.41 0.00
Lesion area 0.65 0.07 0.69 0.00
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cells, which are necessary for angiogensis [20]. Future
intervention studies are required to determine whether
modifying the inflammatory response may limit cellular
injury in acute ischaemic stroke.
Results in context of other studies
S100B has previously been found to be correlated with
CRP in subjects with acute ischaemic stoke at 12, 24
and 72 hours after stroke, after controlling for gender,
age and leukocyte count [21]. The present results extend
those findings to show that the association between CRP
and S100B is also independent of infarct size and a
range of other potentially confounding variables.
Since our study was planned there has been an accu-
mulation of data regarding the potential importance of
inflammation and S100B concentrations in subjects with
acute ischaemic stroke and other neurologic disorders.
Both CRP concentrations at 72 hours, and S100B con-
centrations at twelve hours, have been found to be inde-
pendently associated with clinical outcome following
acute ischaemic stroke [22]. At nano-molar levels S100B
has trophic effects which may an adaptive response to
brain injury. However S100B at micromolar concentra-
tions, may itself have neurotoxic (apoptotic) effects [23].
Over-expression of S100B has now been documented in
a range of brain diseases [23]. Thus, although we were
interested in S100B as a surrogate marker of clinical
outcome, the higher concentrations of S100B may
potentially cause, rather than simply reflecting, the
degree of brain injury.
S100B also has pro-inflammatory effects. Although
S100B is thought to be brain-specific, raised concentra-
tions of S100B have been observed in systemic diseases
without apparent neurologic involvement. Among subjects
with systemic lupus erythematosus, concentrations of
S100B were elevated (relative to controls) among subjects
without central nervous system involvement, although to a
lesser extent than among subjects with neurologic or psy-
chiatric manifestations [24]. This could be because S100B
is a sensitive marker of sub-clinical neurologic disease. It
has since been postulated that S100B may act as an
inflammatory mediator in subjects with non-neurologic
disease. However S100B was found not to be associated
with CRP in renal transplant recipients [25].
Strengths of our study
Ours is one of few studies to simultaneously assess
infarct size, clinical variables and systemic markers of
inflammation, oxidative stress and vascular function. We
used a conservative approach in the modeling exercise.
We included both sensitive clinical scales and imaging
measures. For example, the NIHSS correlates with
infarct volume (r = 0.68) and is a strong predictor of
outcome after stroke [26,27]. Thus substantial residual
confounding of the observed association between
inflammation and S100B concentrations by lesion sever-
ity seems unlikely. We also accounted for the heteroge-
neity of acute ischaemic stroke syndromes by assessing
stroke aetiology and clinical sub-type.
Limitations
There are several limitations to the study. We did not
assess for other potential causes of inflammation (such
as deep venous thrombosis and pulmonary atelectasis)
which may confound the association between neurologic
lesions and inflammation. Other potential confounding
variables which were not controlled for include the
degree of leukoariosis, and medical therapies. Determin-
ing lesion volume (rather than lesion size in one plane)
would also have allowed greater confidence that differ-
ences due to lesion severity were adequately controlled
in the multivariate models.
Interpretation of our results is also limited as S100B
was only measured once. We were thus unable to
account for differences in inflammatory status prior to
the acute stroke event. The cross sectional design pre-
vents any causal inferences being made. In addition, ele-
vated S100B concentrations are not specific to ischaemic
brain injury and the pattern of change in S100B levels is
variable depending on the stroke subtype. Overall, serum
S100B levels peak 2-3 days after an ischaemic stroke [12].
However in large middle cerebral artery (MCA) territory
strokes serum S100B levels may not peak until 7 days
[11]. Despite this variability, single S100B concentrations
measured 2-3 days after non-lacunar ischaemic stroke
were found to provide optimal predictive value compared
to more complex measures [28]. Although S100B consis-
tently appears to predict outcomes, data from subjects
with traumatic brain injury indicate that the relationship
between inflammation and alternative markers of brain
injury (such as neuron specific enolase) may also warrant
examination in subjects with acute ischaemic stroke [29].
Conclusion
T h ed e g r e eo fs y s t e m i ci n f l a m m a t i o ni si n d e p e n d e n t l y
associated with S100B concentrations in subjects with
acute ischaemic stroke.
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